<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918214</url>
  </required_header>
  <id_info>
    <org_study_id>I16018 (PRODIASYS2)</org_study_id>
    <nct_id>NCT02918214</nct_id>
  </id_info>
  <brief_title>Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock</brief_title>
  <acronym>PRODIASYS2</acronym>
  <official_title>Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIC 1415 INSERM - Tours University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis induces a reversible systolic and diastolic cardiac dysfunction. The presence of a
      left ventricular (LV) diastolic dysfunction during septic shock could favor harmful volume
      overload. Recently, a meta-analysis suggested a negative prognostic role of LV diastolic
      dysfunction in septic patients (Od Ratio: 1.82; 95%CI: 1.12 - 2.97; p = 0.02) but its
      external validity is hampered by the numerous limits and the heterogeneity of the studies. To
      date, a pathophysiological link between LV diastolic dysfunction associated with septic shock
      and the water balance (reflecting volume overload) remains to establish. In addition, small
      size studies reported an excess of mortality in patients with septic shock who were diagnosed
      with a high cardiac output. However, no large cohort has yet confirmed the negative
      prognostic role of a hyperkinetic hemodynamic profile at the initial phase of septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients diagnosed with septic shock will be followed daily using
      echocardiography from Day1 (first echocardiography performed within 12h after the diagnosis
      of septic shock) to Day3, after vasopressor discontinuation (Day end), and on Day28 or at
      hospital discharge (if occurs before Day28). Echocardiographic data will be anonymized and
      stored in DICOM format in a dedicated database for independent measurements by an expert in
      echocardiography blinded from the clinical data of the patients including vital status. Vital
      and biological parameters usually monitored for the management of septic shock will be
      collected at the time of each echocardiographic assessment. Patients' vital status will be
      collected on Day28. The potential influence of LV diastolic dysfunction and LV hyperkinesia
      on prognosis will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Day 28</time_frame>
    <description>Survival at one month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily water balance</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>The daily water balance (from Day1 to Day3 included) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated water balances</measure>
    <time_frame>Day 4</time_frame>
    <description>The cumulated water balance on Day4 (sum of water balances recorded from Day1 to Day3 included) will be calculated</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Septic Shock</condition>
  <condition>Echocardiography</condition>
  <condition>Diastolic Dysfunction</condition>
  <condition>Hyperkinesia</condition>
  <arm_group>
    <arm_group_label>echocardiography</arm_group_label>
    <description>Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited in the ICU but also in Emergency Departments if they present
        with septic shock before ICU admission
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient hospitalized in ICU for septic shock:

               -  Documented or highly suspected infection (clinically or microbiologically)

               -  Causing an organ failure defined as an acute change in total SOFA score ≥ 2
                  points (baseline SOFA score can be assumed to be zero in the absence of
                  pre-existing organ dysfunction)

               -  And low blood pressure (sBP &lt; 90 mmHg or a decrease of more than 40 mmHg compared
                  to baseline, or mBP &lt; 65 mmHg) despite a fluid loading of 30 mL/kg (except if
                  clinical or radiological sign of pulmonary fluid overload) requiring vasopressor
                  infusion to maintain mBP &gt; 65 mmHg

               -  And lactate level &gt; 2 mmol/L

          -  Patient older than 18 years old affiliated to the French Social Security

          -  Non-opposition of the patient (or of its next-of-kin) to participate in the study

        Exclusion Criteria:

          -  Ongoing dobutamine or epinephrine infusion

          -  Severe left valvular disease (severe stenosis, severe regurgitation ≥ grade 3)

          -  Constrictive pericarditis (invalidate the mitral tissue Doppler imaging)

          -  Pregnant women

          -  Patient with estimated life expectancy &lt; 24h.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine GOUDELIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marine GOUDELIN, MD</last_name>
    <phone>+33555056240</phone>
    <email>marine.goudelin@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul BOURZEIX</last_name>
    <phone>+335558841</phone>
    <email>paul.bourzeix@chu-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel SLAMA, MD</last_name>
      <phone>+33322455854</phone>
      <email>slama.michel@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Michel SLAMA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien MAIZEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loay KONTAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwanaël PRAT, MD</last_name>
      <phone>+33298347181</phone>
      <email>gwenael.prat@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gwanaël PRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BAILLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline GONZALEZ, MD</last_name>
      <phone>+33555056240</phone>
      <email>celine.gonzalez@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Paul BOURZEIX</last_name>
      <phone>+33555058841</phone>
      <email>paul.bourzeix@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Céline GONZALEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe VIGNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno FRANCOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas PICHON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas DAIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LEVY, MD</last_name>
      <phone>383154084</phone>
      <phone_ext>+33</phone_ext>
      <email>b.levy@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno LEVY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas AUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline FRITZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine KIMMOUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon LEMOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu MATTEI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre PEREZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine THIVILLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle SIMONOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire MULLER, MD</last_name>
      <phone>238229534</phone>
      <phone_ext>+33</phone_ext>
      <email>gregoire.muller@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Grégoire MULLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François BARBIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalila BENZEKRI LEFEVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry BOULAIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne BRETAGNOL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toufik KAMEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle MATHONNET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mai-Anh NAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RUNGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie SKARZYNCKI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Ambroise Paré</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine VIEILLARD-BARON, MD</last_name>
      <phone>+33149095603</phone>
      <email>antoine.vieillard-baron@apr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine VIEILLARD-BARON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier REPESSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril CHARRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence BOISSIER, MD</last_name>
      <phone>549444367</phone>
      <phone_ext>+33</phone_ext>
      <email>florence.boissier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Florence BOISSIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Pierre FRAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine CHATELLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole GUIGNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline DELETAGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgane OLIVRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix Guyon Hospital</name>
      <address>
        <city>Saint Denis DE LA Reunion</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David VANDROUX, MD</last_name>
      <phone>+33262905690</phone>
      <email>vandroux.david@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David VANDROUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas GALAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MARTINET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien JABOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silva STEIN, MD</last_name>
      <phone>+33561772288</phone>
      <email>silva.s@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Silva STEIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick LEGRAS, MD</last_name>
      <phone>+33247473855</phone>
      <email>a.legras@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Annick LEGRAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle MERCIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis GAROT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <keyword>echocardiography</keyword>
  <keyword>diastolic dysfunction</keyword>
  <keyword>Transthoracic</keyword>
  <keyword>Transesophageal</keyword>
  <keyword>hyperkinesia</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

